Abstract
BACKGROUND: Tebipenem is a broad-spectrum orally administered carbapenem antibiotic that could be an alternative to IV carbapenems. The current study evaluated in vitro activity of tebipenem against bacterial isolates recovered from patients with cancer. METHODS: A total of 611 bacterial pathogens recently isolated from patients with cancer were tested for susceptibility to tebipenem and comparators. CLSI-approved broth microdilution methods were used. MIC(50), MIC(90), MIC range and percentage susceptibility calculations were made using FDA breakpoints when available. RESULTS: Tebipenem had a low MIC(90) for most Gram-positive and Enterobacterales isolates. Tebipenem MIC(90) ranged from 0.06 to 0.25 mg/L for all tested Enterobacterales. CONCLUSIONS: Oral tebipenem has promising activity against clinically significant bacterial pathogens isolated from patients with cancer. Further clinical evaluation of tebipenem for the treatment of bacterial infections in patients with cancer is warranted.